Valeant reports positive results from IDP-118 Phase III clinical study

Valeant Pharmaceuticals has reported positive results from a Phase III clinical study to evaluate the safety of IDP-118 (halobetasol propionate and tazarotene) lotion in the treatment of plaque psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news